Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial.

Autor:	Itariu, Bianca K., Zeyda, Maximilian, Hochbrugger, Eva E., Neuhofer, Angelika, Prager, Gerhard, Schindler, Karin, Bohdjalian, Arthur, Mascher, Daniel, Vangala, Suman, Schranz, Michael, Krebs, Michael, Bischof, Martin G., Stulnig, Thomas M.
Předmět:	THERAPEUTIC use of omega-3 fatty acids ADIPOSE tissues ANALYSIS of covariance ANALYSIS of variance BIOMARKERS C-reactive protein CHOLESTEROL CYTOKINES GENE expression GENETIC polymorphisms HIGH density lipoproteins INFLAMMATION INTERLEUKINS LOW density lipoproteins OMEGA-3 fatty acids HEALTH outcome assessment POLYMERASE chain reaction RESEARCH funding STATISTICS T-test (Statistics) TRIGLYCERIDES SAMPLE size (Statistics) DATA analysis MORBID obesity RANDOMIZED controlled trials TREATMENT effectiveness REPEATED measures design REVERSE transcriptase polymerase chain reaction DATA analysis software DISEASE complications THERAPEUTICS
Zdroj:	American Journal of Clinical Nutrition; Nov2012, Vol. 96 Issue 5, p1137-1149, 13p, 1 Diagram, 2 Charts, 5 Graphs
Abstrakt:	Background: Chronic adipose tissue inflammation is a hallmark of obesity, triggering the development of associated pathologies, particularly type 2 diabetes. Long-chain n-3 PUFAs reduce cardiovascular events and exert well-established antiinflammatory effects, but their effects on human adipose tissue inflammation are unknown. Objective: We investigated whether n-3 PUFAs reduce adipose tissue inflammation in severely obese nondiabetic patients. Design: We treated 55 severely obese nondiabetic patients, scheduled to undergo elective bariatric surgery, with 3.36 g long-chain n-3 PUFAs/d (EPA, DHA) or an equivalent amount of butterfat as control, for 8 wk, in a randomized open-label controlled clinical trial. The primary efficacy measure was inflammatory gene expression in visceral and subcutaneous adipose tissue samples (subcutaneous adipose tissue and visceral adipose tissue), collected during surgery after the intervention. Secondary efficacy variables were adipose tissue production of antiinflammatory n-3 PUFA-derived eicosanoids, plasma concentrations of inflammatory markers, metabolic control, and the effect of the Pro 12Ala PPARG polymorphism on the treatment response. Results: Treatment with n-3 PUFAs, which was well tolerated, decreased the gene expression of most analyzed inflammatory genes in subcutaneous adipose tissue (P < 0.05) and increased production of antiinflammatory eicosanoids in visceral adipose tissue and subcutaneous adipose tissue (P < 0.05). In comparison with control subjects who received butterfat, circulating interleukin-6 and triglyceride concentrations decreased significantly in the n-3 PUFA group (P = 0.04 and P = 0.03, respectively). The Pro12Ala polymorphism affected the serum cholesterol response to n-3 PUFA treatment. Conclusions: Treatment with long-chain n-3 PUFAs favorably modulated adipose tissue and systemic inflammation in severely obese nondiabetic patients and improved lipid metabolism. These effects may be beneficial in the long-term treatment of obesity. This trial was registered at clinicaltrials.gov as NCT00760760. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu